Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in London
SAN FRANCISCO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
SAN FRANCISCO, Nov. 09, 2026 (GLOBE NEWSWIRE) — Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that the Company will participate in the Jefferies Global Healthcare Conference in London, being held November 16-19, 2026. Management will participate in a fireside chat on Wednesday, November 18, 2026, at 1:30 p.m. GMT / 8:30 a.m. ET.
Interested parties may access a live webcast by visiting the News & Events section of the Braveheart Bio website at https://ir.braveheart.bio/, with a replay available in a temporary archive following the event.
About Braveheart Bio
Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio’s lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart Bio is aiming to address the limitations of currently available CMIs by designing BHB-1893 for rapid onset, consistent depth of response, preservation of systolic function, prompt reversibility, and a straightforward approach to titration and monitoring. For more information, please visit www.braveheart.bio.
Investor Relations Contact
Alexander Sharif
New Street Investor Relations
Alexander@NewStreetIR.com
Media Contact
FGS Global
Braveheart-bio@fgsglobal.com
Media gallery
